CAR T-cell therapy for relapsed/refractory CD5-positive diffuse large B-cell lymphoma yields more favorable outcomes than standard therapy.
作者信息
Luo Hui, Li Tongjuan, Meng Fankai, Hong Zhenya, Cao Yang, Wang Gaoxiang, Huang Liang, Zhou Xiaoxi
机构信息
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan 430030, China.
出版信息
Cancer Biol Med. 2025 May 6;22(5):496-501. doi: 10.20892/j.issn.2095-3941.2024.0626.
Abstract
摘要
Zotero 插件